FDA Approves New Breast Cancer Drug

  • Health
FDA Approves New Breast Cancer Drug

Novartis AG’s combination therapy of hormone therapy for postmenopausal women, as well as for men, with a form of advanced breast cancer has been approved by the U.S. Food and Drug Administration (FDA).

The alpelisib drug, marketed under the brand name Piqray, belongs to a class of drugs known as PI3K inhibitors.

“Piqray is the first PI3K inhibitor to demonstrate a clinically meaningful benefit in treating patients with this type of breast cancer,” the FDA said in a statement.

The combination therapy treats hormone receptor positive, HER2-negative breast cancer with mutations of the PIK3CA gene which are the most common genetic change in hormone-receptor positive breast cancer.

Source: Kataeb.org